• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by GRAIL Inc.

    3/12/26 4:45:48 PM ET
    $GRAL
    Medical Specialities
    Health Care
    Get the next $GRAL alert in real time by email
    S-8 1 gral-sx8esppevergreenxmar2.htm S-8 Document


    As filed with the Securities and Exchange Commission on March 12, 2026
    Registration No. 333-

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    FORM S-8 
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
     
     
    GRAIL, Inc.
    (Exact name of Registrant as specified in its charter)
     
     
     
    Delaware 86-3673636
    (State or other jurisdiction of
    incorporation or organization)
     
    (I.R.S. Employer
    Identification No.)
    1525 O’Brien Drive
    Menlo Park, California
     94025
    (Address of Principal Executive Offices) (Zip Code)

    2024 Incentive Award Plan
    2024 Employee Stock Purchase Plan
    (Full Title of the Plans)

    Abram Barth
    General Counsel and Secretary
    GRAIL, Inc.
    1525 O’Brien Drive
    Menlo Park, California 94025
    (Name and Address of Agent for Service)

    (833) 694-2553
    (Telephone Number, Including Area Code, of Agent for Service)

    Copies to:




    W. Alex Voxman
    Andrew Clark
    Ross McAloon
    Emily Corbi
    Latham & Watkins LLP
    355 South Grand Avenue, Suite 100
    Los Angeles, California 90071
    (213) 485-1234


     
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
     
    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
      Emerging growth company ☒
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒



    EXPLANATORY NOTE
    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 317,335 shares of the common stock of GRAIL, Inc. (the “Registrant”) to be issued pursuant to the GRAIL, Inc. 2024 Employee Stock Purchase Plan (the “ESPP”) and an additional 368,055 shares of the common stock of the Registrant to be issued under the GRAIL, Inc. 2024 Incentive Award Plan (together with the ESPP, the “Plans”). A Registration Statement of the Registrant on Form S-8 relating to the Plans is effective.
    INCORPORATION BY REFERENCE OF CONTENTS OF
    REGISTRATION STATEMENT ON FORM S-8
    Except as set forth below, the contents of the Registration Statements on Forms S-8 (Files No. 333-280424 and 333-285580), including any amendments thereto, filed with the Securities and Exchange Commission, relating to the Plans, are incorporated by reference herein.

    Item 8.Exhibits
     
    Exhibit
    Number
    Exhibit DescriptionFormIncorporated by Reference
    Date
    Number
    Filed
    Herewith
    4.1
    Certificate of Incorporation of GRAIL, Inc.
    8-K06/24/20243.1
    4.2
    Amended and Restated Bylaws of GRAIL, Inc.
    8-K06/24/20243.2
    5.1
    Opinion of Latham & Watkins LLP
    X
    23.1
    Consent of Independent Registered Public Accounting Firm
    X
    23.2
    Consent of Latham & Watkins LLP (included in Exhibit 5.1)
    X
    24.1
    Power of Attorney (included on signature page)
    99.1
    Form of 2024 Employee Stock Purchase Plan
    8/K/A07/02/202410.2
    99.2
    GRAIL, Inc. 2024 Incentive Award Plan
    8/K/A07/02/202410.1
    99.3
    Form of Restricted Stock Unit Award Agreement
    10-12B/A5/29/202410.9
    99.4
    Form of Stock Option Agreement
    10-12B/A5/29/202410.10
    107.1
    Registration Fee Table
    X




    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Menlo Park, State of California, on this 12th of March, 2026.
     
    GRAIL, INC.
    By: /s/ Robert Ragusa
     Name: Robert Ragusa
     Title: Chief Executive Officer
    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Robert Ragusa, Abram Barth and Donald Lang, and each of them, with full power of substitution and full power to act without the other, as his true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file this Registration Statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.




    Signature Title Date
    /s/ Robert Ragusa
     
    Director and Chief Executive Officer
     March 12, 2026
    Robert Ragusa
    (Principal Executive Officer)
    /s/ Aaron Freidin
     
    Chief Financial Officer
     March 12, 2026
    Aaron Freidin
    (Principal Financial Officer and
    Principal Accounting Officer)
    /s/ William Chase 
    Director
     March 12, 2026
    William Chase
    /s/ Sarah Krevans 
    Director
     March 12, 2026
    Sarah Krevans
    /s/ Steven Mizell
     
    Director
     March 12, 2026
    Steven Mizell
    /s/ Gregory Summe
     
    Director and Chairperson of the Board
     March 12, 2026
    Gregory Summe


    Get the next $GRAL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GRAL

    DatePrice TargetRatingAnalyst
    2/19/2026$114.00Hold
    TD Cowen
    2/17/2026$113.00Outperform
    Robert W. Baird
    12/2/2025$110.00Equal-Weight
    Morgan Stanley
    11/12/2025$100.00Neutral → Buy
    Guggenheim
    4/21/2025$32.00Buy
    Canaccord Genuity
    11/27/2024$16.00Equal-Weight
    Morgan Stanley
    11/15/2024Peer Perform
    Wolfe Research
    10/17/2024Neutral
    Guggenheim
    More analyst ratings

    $GRAL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor

    MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that Bob Ragusa will retire as Chief Executive Officer, effective June 1, 2026. GRAIL's Board of Directors has appointed the Company's President, Josh Ofman, MD, MSHS, to serve as GRAIL's Chief Executive Officer upon Ragusa's retirement. In addition, Ofman has been appointed to GRAIL's Board of Directors, effective immediately. Ofman's appointment is the culmination of a long-term comprehensive succession planning process to ensure leadership continuity and strategic execution. Ragusa will remain on GRAIL's Board unti

    3/12/26 4:30:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    MENLO PARK, Calif., March 2, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 19,500 shares of GRAIL's common stock to 20 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

    3/2/26 4:01:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL to Present at the TD Cowen 46th Annual Health Care Conference

    MENLO PARK, Calif., Feb. 24, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the TD Cowen 46th Annual Health Care Conference in Boston on Tuesday, Mar. 3 at 10:30 a.m. ET.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.About GRAILGRAIL is a healthcare company whose mission is to dete

    2/24/26 4:02:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ding Chun R bought $1,024,698 worth of shares (78,829 units at $13.00) and acquired $879,900 worth of shares (70,000 units at $12.57) (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    10/10/24 7:45:32 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Freidin Aaron sold $154,062 worth of shares (3,147 units at $48.96), decreasing direct ownership by 1% to 306,475 units (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    3/9/26 9:36:07 PM ET
    $GRAL
    Medical Specialities
    Health Care

    President Ofman Joshua J. sold $177,227 worth of shares (3,627 units at $48.86), decreasing direct ownership by 0.83% to 432,881 units (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    3/9/26 9:36:01 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Chief Executive Officer Ragusa Robert P sold $409,246 worth of shares (8,441 units at $48.48), decreasing direct ownership by 1% to 642,084 units (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    3/9/26 9:35:55 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on GRAIL with a new price target

    TD Cowen initiated coverage of GRAIL with a rating of Hold and set a new price target of $114.00

    2/19/26 7:51:30 AM ET
    $GRAL
    Medical Specialities
    Health Care

    Robert W. Baird initiated coverage on GRAIL with a new price target

    Robert W. Baird initiated coverage of GRAIL with a rating of Outperform and set a new price target of $113.00

    2/17/26 8:18:22 AM ET
    $GRAL
    Medical Specialities
    Health Care

    Morgan Stanley resumed coverage on GRAIL with a new price target

    Morgan Stanley resumed coverage of GRAIL with a rating of Equal-Weight and set a new price target of $110.00

    12/2/25 8:25:57 AM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    SEC Filings

    View All

    SEC Form S-8 filed by GRAIL Inc.

    S-8 - GRAIL, Inc. (0001699031) (Filer)

    3/12/26 4:45:48 PM ET
    $GRAL
    Medical Specialities
    Health Care

    SEC Form 10-K filed by GRAIL Inc.

    10-K - GRAIL, Inc. (0001699031) (Filer)

    3/12/26 4:40:47 PM ET
    $GRAL
    Medical Specialities
    Health Care

    SEC Form 144 filed by GRAIL Inc.

    144 - GRAIL, Inc. (0001699031) (Subject)

    3/5/26 9:12:22 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Leadership Updates

    Live Leadership Updates

    View All

    GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor

    MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that Bob Ragusa will retire as Chief Executive Officer, effective June 1, 2026. GRAIL's Board of Directors has appointed the Company's President, Josh Ofman, MD, MSHS, to serve as GRAIL's Chief Executive Officer upon Ragusa's retirement. In addition, Ofman has been appointed to GRAIL's Board of Directors, effective immediately. Ofman's appointment is the culmination of a long-term comprehensive succession planning process to ensure leadership continuity and strategic execution. Ragusa will remain on GRAIL's Board unti

    3/12/26 4:30:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL Appoints Sarah Krevans to Board of Directors

    MENLO PARK, Calif., Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Ms. Krevans will also serve as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Governance Committee. Following the appointment of Ms. Krevans, the Board will be composed of five directors, four of whom are independent. Ms. Krevans served as president and CEO of Sutter Health, a Northern

    10/21/24 4:01:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Wheels Up Announces Gregory Summe to Join Board of Directors

    Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

    8/8/24 8:05:00 AM ET
    $AVTR
    $GRAL
    $NXPI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care

    $GRAL
    Financials

    Live finance-specific insights

    View All

    GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results

    Sold More Than 185,000 Galleri® Tests in 2025, Growing U.S. Galleri Revenue 26% Year-Over-Year to $136.8 MillionCompleted Galleri PMA Submission to FDAShared Topline Results from the NHS-Galleri TrialCompleted Analysis of the Full 35k Participant PATHFINDER 2 StudyStrong Financial Position with Cash into 2030MENLO PARK, Calif., Feb. 19, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2025 and provided business updates.

    2/19/26 4:02:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results

    MENLO PARK, Calif., Feb. 16, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter and full year 2025 following the close of market on Thursday, Feb. 19, 2026. Following the release, company management will host a webcast and conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss results and business progress. Fourth Quarter and Full Year 2025 Webcast and Conference Call DetailsA link to the live webcast and recorded replay w

    2/16/26 9:00:00 AM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL Reports Third Quarter 2025 Financial Results

    Q3 U.S. Galleri Revenue Grew 28% Year-Over-Year to $32.6 Million Q3 Galleri Tests Sold Grew 39% Year-Over-Year to More Than 45,000 Galleri PMA Submission to FDA Now Anticipated in Q126 Cash Position of More Than $850 Million Includes Recently Completed Private Placement MENLO PARK, Calif., Nov. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter of 2025. Total revenue in the third quarter grew 26% year-over-year to $36.2 million

    11/12/25 4:02:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by GRAIL Inc.

    SC 13G - GRAIL, Inc. (0001699031) (Subject)

    11/14/24 3:35:14 PM ET
    $GRAL
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by GRAIL Inc.

    SC 13G - GRAIL, Inc. (0001699031) (Subject)

    11/12/24 4:47:47 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by GRAIL Inc.

    SC 13G/A - GRAIL, Inc. (0001699031) (Subject)

    9/30/24 6:42:39 PM ET
    $GRAL
    Medical Specialities
    Health Care